Summary
The Cigna Group's 2025 10-K filing highlights a strong financial performance, with shareholders' net income increasing by 73% year-over-year, primarily driven by the absence of a prior year impairment charge. Adjusted income from operations also saw a healthy 4% increase, reflecting the company's ongoing operational efficiency and strategic initiatives. The divestiture of its Medicare Advantage and related businesses to HCSC in March 2025 contributed to a decrease in medical customers but also led to a significant cash inflow and strategic realignment. Evernorth Health Services continues to be a strong performer, with adjusted revenues up 16% and pre-tax adjusted income from operations increasing by 3%, driven by growth in Pharmacy Benefit Services and Specialty and Care Services. Cigna Healthcare experienced a revenue decline of 11%, largely due to the HCSC divestiture, though the ongoing U.S. Healthcare businesses saw improvement in premiums. The company is also investing in innovation, including a rebate-free pharmacy benefits model, which is expected to impact short-term earnings but enhance long-term value and transparency.
Financial Highlights
52 data points| Revenue | $274.90B |
| Cost of Revenue | $214.99B |
| Gross Profit | $59.91B |
| SG&A Expenses | $14.62B |
| Operating Income | $9.20B |
| Interest Expense | $1.40B |
| Net Income | $6.29B |
| EPS (Basic) | $22.33 |
| EPS (Diluted) | $22.18 |
| Shares Outstanding (Diluted) | 268.56M |
Key Highlights
- 1Shareholders' net income surged by 73% to $5.96 billion in 2025, largely due to the absence of a significant impairment charge recorded in the prior year.
- 2Adjusted income from operations increased by 4% to $8.01 billion, demonstrating continued underlying business strength.
- 3Evernorth Health Services showed robust growth, with adjusted revenues up 16% to $235 billion and pre-tax adjusted income from operations rising 3% to $7.22 billion.
- 4Cigna Healthcare's adjusted revenues decreased by 11% to $47.16 billion, primarily impacted by the divestiture of its Medicare Advantage and related businesses.
- 5The company completed the sale of its Medicare Advantage and related businesses to HCSC in March 2025 for $4.9 billion, as part of its strategic portfolio optimization.
- 6The Cigna Group is investing in a new rebate-free pharmacy benefits model, expected to lower medication costs and improve transparency, with an anticipated annualized after-tax savings of at least $500 million.
- 7Total medical customers decreased by 5%, primarily reflecting the impact of the HCSC transaction.